GLP-1s like Ozempic and Wegovy are transforming obesity medicine, but the story doesn’t end at weight loss. Clinical trials show that 25–40% of the weight lost on GLP-1s comes from lean mass, including muscle. Muscle is your biggest site for glucose disposal, a key regulator of metabolism, and a major factor in long-term weight maintenance. History backs this up: analysis of the Minnesota Starvation Experiment showed that the best predictor of rebound weight gain wasn’t how much fat people lost,

At least 3,000 patients have filed lawsuits against the companies behind GLP-1 weight loss drugs, alleging severe health risks, including blindness. NewsNation's Brooke Shafer has the story on "Morning in America." | NewsNation